Clinical Trial Update: Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update comparing Percutaneous Hepatic Perfusion to Cisplatin/Gemcitabine in intrahepatic cholangiocarcinoma (bile duct cancer) across Phase 2 and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Cancer
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Cisplatin/Gemcitabine
• Percutaneous Hepatic Perfusion

Snippet

Sponsor: Delcath Systems Inc. | Conditions: Bile Duct Cancer, Intrahepatic Cholangiocarcinoma | Phase 2, Phase 3 | Status: UNKNOWN